TL;DR
Researchers at the University of Cambridge and start-up GlitterinTech report a compact optical spectrometer designed to combine low cost with precise measurements. In reported tests, it identified several materials and measured solutions and biomarkers, including noninvasive glucose tracking in one participant; further research is needed before it can be used as a medical product.
Researchers at the University of Cambridge and the start-up GlitterinTech report developing a compact optical spectrometer that costs about $10 and could be incorporated into portable or wearable devices. Their experiments included measurements of several biomarkers and noninvasive glucose tracking in one participant, but the results do not establish that the device is ready for medical use or can replace established glucose monitors.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The device, called a convolutional spectrometer, is built on a silicon nitride photonic platform and includes onboard electronics. The team reports that it measures near-infrared light across 1,200 to 1,700 nanometers and collects and processes a measurement in less than a second. Optical spectrometers infer information about materials by analyzing how they interact with light, but conventional miniaturized versions can lose measurement range, resolution or accuracy.
The researchers tested the system on plastics, pharmaceuticals, coffee, flour and tea. They report a 100% classification success rate in those tests. In experiments measuring concentrations in water-based and organic solutions, they report accuracy of about 0.01%, and say the results exceeded those from commercial benchtop spectrometers in the experiments. The reported figures describe the study’s tests; the source material does not provide enough detail to treat them as general performance guarantees.
For biomedical demonstrations, the team reports measuring skin moisture, blood alcohol, blood lactate and blood glucose under conditions intended to reflect physiological environments. It also reports tracking glucose without needles over an extended period in one participant. The account says further testing is necessary before practical medical deployment. The researchers also report that the instrument continued operating from -20°C to 80°C, a range that could matter for wearable, industrial and outdoor sensing.
Potential Uses Beyond the Lab
If the reported performance can be reproduced outside controlled experiments, a small and inexpensive spectrometer could make some forms of chemical measurement available in settings where a benchtop instrument is impractical. That could include wearable devices, food checks, industrial quality control and environmental monitoring. The low stated component cost is relevant because it may make portable sensing more accessible, though the source does not establish the final price of a finished product.
The glucose demonstration has particular public interest because it points toward a possible way to monitor blood sugar without repeated skin punctures. But a test in one participant is preliminary evidence, not proof of reliable performance across people or everyday conditions. Medical devices must be evaluated for accuracy, safety and consistency before consumers or clinicians can rely on them.
The researchers say the system’s design also reduces computational requirements. They describe a possible route to expanding its bandwidth and resolution by adding repeated optical components. Those are stated capabilities of the approach; the source does not show that every proposed expansion has been built or validated in a commercial device.
Products Worth Considering

Withings BPM Vision Blood Pressure Monitor

Levoit Vital 100S-P Air Purifier for Home and Pets

Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Whitestone
As an affiliate, we earn on qualifying purchases.
How the Optical Design Works
Traditional spectrometers commonly separate incoming light into wavelengths or use calculations to reconstruct a spectrum. The Cambridge team’s design instead uses optical components with repeating spectral responses, including possible unbalanced Mach-Zehnder interferometers or micro-ring resonators. Arranged in sequence and adjusted proportionally, the components shift their wavelength response in a controlled way. The system then applies fast Fourier transforms to recover the spectrum.
The approach draws on the convolution theorem, a mathematical principle the team says allows it to process light differently from existing compact designs. According to the researchers, performing the operation in the optical domain helps limit noise and computational demands while maintaining precision. They say the instrument’s pattern-based architecture could be extended by adding components, although practical limits and product specifications are not detailed in the supplied report.
The work was developed by university researchers and GlitterinTech, a start-up founded by the same research group. The report describes tests across materials, solutions and biomarkers, but does not provide independent clinical validation or evidence that the device is already being sold as a wearable medical sensor.
“The key insight was to go back to the mathematics and ask whether there was a fundamentally cleaner way to retrieve spectra.”
— Dr. Chunhui Yao, lead author
Clinical Validation Still Needed
The central unknown is whether the device can measure glucose accurately and consistently across a larger, diverse group of people and in everyday settings. The source describes a noninvasive demonstration in one participant but does not provide clinical trial results, detailed error rates for glucose readings, or comparisons with established glucose-monitoring methods across multiple users.
It is also unclear what testing, regulatory review or product development would be required before a wearable version could be marketed for health monitoring. The reported $10 cost refers to the sensor, not necessarily the complete device, manufacturing, calibration or ongoing operation. The report does not specify a release schedule, commercial availability or independent replication of the results.
Further Tests Before Wearables
The research team’s next challenge is to establish how well the spectrometer performs in larger and more varied tests, particularly for glucose monitoring. That would need to clarify accuracy across users and conditions and show how measurements compare with accepted methods. The supplied report does not name a trial schedule, regulatory milestone or planned launch date.
For applications in food testing, manufacturing and environmental monitoring, the device would also need validation for the specific substances and operating conditions involved. Until those steps are reported, the work is best understood as a promising research demonstration, rather than a medical product available for consumers.
Key Questions
What did the Cambridge researchers develop?
They report developing a compact convolutional optical spectrometer on a silicon nitride photonic platform, with onboard electronics. It analyzes near-infrared light and is reported to cost about $10 as a sensor.
Can it monitor blood glucose without needles?
The researchers report noninvasive glucose tracking over an extended period in one participant. That is a preliminary demonstration, not proof that the device is ready to monitor glucose reliably for the general public.
What else did the team test it on?
The report describes tests involving plastics, pharmaceuticals, coffee, flour and tea, as well as concentrations in water-based and organic solutions. The team also reports measurements of skin moisture, blood alcohol and blood lactate.
Is the $10 sensor available to buy?
The source does not say that the sensor or a wearable product is commercially available. The stated figure is the reported sensor cost, and it may not represent the price of a complete device or finished medical product.
What remains to be shown?
Further research is needed to test performance across more people and real-world conditions, especially for glucose measurements. The supplied report does not give clinical validation results, regulatory status or a product release date.
Source: rss
